// App-Quantinova.ai

CTNI-54 : A SINGLE ARM PHASE II STUDY OF THE DUAL MTORC1/MTORC2 INHIBITOR VISTUSERTIB PROVIDED FOR SPORADIC PATIENTS WITH GRADE II-III MENINGIOMAS THAT RECUR OR PROGRESS AFTER SURGERY AND RADIATION

Researchers

Presenter

  • Scott Plotkin

Principal Investigators

  • Priya Kumthekar

  • Patrick Wen

  • Fred Barker

  • Roberta Beauchamp

  • Elizabeth Gerstner

  • Alona Muzikansky

  • Miriam Smith

  • Anat Stemmer-Rachamimov

  • Justin Jordan

  • Vijaya Ramesh

Medical Centers

  • Northwestern Medicine; Feinberg School of Medicine, Chicago, IL, USA

  • Massachusetts General Hospital, Boston, MA, USA

  • Center for Neuro-Oncology, Dana-Farber Cancer Institute, Boston, MA, USA

  • University of Manchester, Manchester, UK

Locations

  • United States

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Endocrine/metabolic Diseases (ME)

  • Genetic Disorder

  • Cardiovascular (CVS)

  • Gastroenterology (GU)

  • Dental and Oral Health

  • Oncology (ONC)

Disease

  • Dyslipidemia

  • Hypophosphatemic rickets

  • Constipation

  • Hypertension

  • Meningiomas

  • Xerostomia

Biomarkers

  • Alanine transaminase

Drug/Treatment

  • N/A

Outcome

  • N/A

Study Design

  • Single Arm

  • Cross-Sectional

Phase

  • II

Study Id's

  • NCT03071874

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved